Table 1 Baseline demographic and clinical characteristics of included patients
Total | Drug regimen interruption | p value | ||
|---|---|---|---|---|
Yes | No | |||
Sex, n (%) | 0.006 | |||
Female | 34 (60.7) | 12 (42.9) | 22 (78.6) | |
Male | 22 (39.3) | 16 (57.1) | 6 (21.4) | |
Median age (IQR) | 37 (31.5–45.0) | 39.5 (34.5–45.5) | 36.0 (29.5–41.5) | 0.08 |
Education, n (%) | 0.14 | |||
Primary | 7 (12.5) | 2 (7.1) | 5 (17.9) | |
Secondary | 21 (37.5) | 14 (50.0) | 7 (25.0) | |
Tertiary | 28 (50.0) | 12 (42.9) | 16 (57.1) | |
Occupation type, n (%) | 0.30 | |||
Non-income generating | 10 (17.9) | 3 (10.7) | 7 (25.0) | |
Income-generating | 46 (82.1) | 25 (89.3) | 21 (75.0) | |
WHO stage at entry | 0.41 | |||
1 | 24 (42.9) | 15 (53.6) | 9 (32.1) | |
2 | 18 (32.1) | 7 (25.0) | 11 (39.3) | |
3 | 12 (21.4) | 5 (17.9) | 7 (25.0) | |
4 | 2 (3.6) | 1 (3.6) | 1 (3.6) | |
Subtype | 0.07 | |||
A1 | 3 (5.4) | 2 (7.1) | 1 (3.6) | |
A3 | 1 (1.8) | 0 (0.0) | 1 (3.6) | |
G | 9 (16.1) | 3 (10.7) | 6 (21.4) | |
G’ | 15 (26.8) | 4 (14.3) | 11 (39.3) | |
CRF02_AG | 23 (41.1) | 16 (57.1) | 7 (25.0) | |
CRF06_cpx | 1 (1.8) | 1 (3.6) | 0 (0.0) | |
Unknown | 4 (7.1) | 2 (7.1) | 2 (7.1) | |
CD4+ Count at entry, n (%) (cells/mL) | 0.62 | |||
< 100 | 14 (25.0) | 8 (28.6) | 6 (21.4) | |
100–199 | 17 (30.4) | 9 (32.1) | 8 (28.6) | |
200–349 | 15 (26.8) | 8 (28.6) | 7 (25.0) | |
≥ 350 | 10 (17.9) | 3 (10.7) | 7 (25.0) | |
VL at entry, n (%) (cp/mL) | 0.58 | |||
< 400 (undetectable) | 12 (21.4) | 5 (17.9) | 7 (25.0) | |
400-999 | 6 (10.7) | 3 (10.7) | 3 (10.7) | |
1000-9999 | 8 (14.3) | 5 (17.9) | 3 (10.7) | |
10,000-99,999 | 18 (32.1) | 11 (39.3) | 7 (25.0) | |
≥ 100,000 | 12 (21.4) | 4 (14.3) | 8 (28.6) | |
Days from program entry to sample, median (IQR) | 362 (196–365) | 365 (364–378) | 213 (168–340) | < 0.0001 |
Days from ART initiation to sample, median (IQR) | 745 (581–1036) | 1036 (986–1107) | 601 (176–704) | < 0.0001 |
Undetectable VL between program entry and sample dates, n (%) | 15 (26.8) | 6 (21.4) | 9 (32.1) | 0.37 |
VL at sample date, n (%) (cp/mL) | < 0.001 | |||
1000–9999 | 18 (32.1) | 0 (0.0) | 18 (64.3) | |
10,000–99,999 | 31 (55.4) | 24 (85.7) | 7 (25.0) | |
≥ 100,000 | 7 (12.5) | 4 (14.3) | 3 (10.7) | |
CD4 count at sample date, median (IQR) | 177 (83–301) | 123 (41–216) | 257 (151–360) | 0.004 |
Average % adherence entry to sample date*, n (%) | 0.11 | |||
< 70 | 3 (5.4) | 0 (0.0) | 3 (10.7) | |
70–79 | 3 (5.4) | 2 (7.1) | 1 (3.6) | |
80–89 | 8 (14.3) | 5 (17.9) | 3 (10.7) | |
90–94 | 8 (14.3) | 6 (21.4) | 2 (7.1) | |
95–99 | 13 (23.2) | 8 (28.6) | 5 (17.9) | |
100 | 21 (37.5) | 7 (25.0) | 14 (50.0) | |